Sandbox: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
| colspan="1" style="text-align:center; background: | | colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | ||
|- | |- | ||
|bgcolor=" | |bgcolor="LightGreen" | '''a.''' LDL-C should be <100 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]]) | ||
|- | |- | ||
|bgcolor=" | |bgcolor="LightGreen" |'''b.''' If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]]) | ||
|- | |- | ||
|bgcolor=" | |bgcolor="LightGreen" |'''c.''' If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination). ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]]) | ||
|- | |- | ||
|bgcolor=" | |bgcolor="LightGreen" |'''d.''' If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]]) | ||
|- | |- | ||
|bgcolor=" | |bgcolor="LightGreen" |'''e.''' Therapeutic options to reduce non HDL - C are more intense LDL - C lowering therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B]]) | ||
|- | |- | ||
|bgcolor=" | |bgcolor="LightGreen" |'''f.''' If triglycerides are ≥500 mg/dL, therapeutic options to prevent pancreatitis are fibrate or niacin before LDL-lowering therapy; and treat LDL-C to goal after triglyceride-lowering therapy. Achieve non-HDL-C <130 mg/dL if possible. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:C]]) | ||
|} | |} | ||
Revision as of 20:30, 2 October 2012
Do Not Delete
| Class I |
| a. LDL-C should be <100 mg/dL. (Level of Evidence: A) |
| b. If baseline LDL-C is ≥100 mg/dL, initiate LDL-lowering drug therapy. (Level of Evidence: A) |
| c. If on-treatment LDL-C is ≥100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination). (Level of Evidence: A) |
| d. If triglycerides are 200 to 499 mg/dL, non-HDL-C should be <130 mg/dL. (Level of Evidence:B) |
| e. Therapeutic options to reduce non HDL - C are more intense LDL - C lowering therapy. (Level of Evidence:B) |
| f. If triglycerides are ≥500 mg/dL, therapeutic options to prevent pancreatitis are fibrate or niacin before LDL-lowering therapy; and treat LDL-C to goal after triglyceride-lowering therapy. Achieve non-HDL-C <130 mg/dL if possible. (Level of Evidence:C) |
| Class III (No Benefit) |
| 1. Genetic testing is not indicated in relatives when the index patient does not have a definitive pathogenic mutation. (Level of Evidence: B) |
| 2. Ongoing clinical screening is not indicated in genotype-negative relatives in families with HOCM. (Level of Evidence: B) |
| Class IIa |
| a. Reduction of LDL-C to <70 mg/dL is reasonable. (Level of Evidence:A) |
| b. If baseline LDL-C is 70 to 100 mg/dL, it is reasonable to treat to LDL-C <70 mg/dL. (Level of Evidence:B) |
| c. If triglycerides are 200 to 499 mg/dL, reduction of non-HDL-C to <100 mg/dL is reasonable. (Level of Evidence:B) |
| d. Therapeutic options to reduce non HDL - C are Niacin (after LDL-C loweing therapy). (Level of Evidence:B) |
| e. Therapeutic options to reduce non HDL - C are Fibrate therapy (after LDL-C loweing therapy). (Level of Evidence:B) |